 |
Drug Information Association 1999 35th Annual Meeting
Baltimore, Maryland
FDA Staff Presentations
- 1999 Pediatric Initiatives: Dianne Murphy, M.D. Associate Director for Pediatrics (Posted 7/02/1999)
- AERS Electronic Submissions Pilot, Deborah Yaplee Center for Drug Evaluation and Research U.S. Food and Drug Administration (Posted 7/02/1999)
- GCP Compliance: Emerging Issues in Worldwide Clinical Trials: David A. Lepay, M.D., Ph.D. Director, Division of Scientific Investigations (Posted 7/02/1999)
- Exclusivity Statistics Dianne Murphy, M.D. Associate Director for Pediatrics (Posted 7/02/1999)
- The Facts About Source Documents: Stan W. Woollen Deputy Director, Division of Scientific Investigations (Posted 7/02/1999)
- MedDRA at the US Food and Drug Administration, Andrea Neal, FDA/CDER (Posted 7/08/1999)
- MedDRA and Pharmacovigilance - The Way Forward, Andrea Neal - FDA/CDER, Kathryn Huntley - MedDRA Maintenance and Support Services Organization, Van Doan and Jason Zielonka - PSI International, Inc (Posted 7/08/1999)
- Safety Assessment in Pediatrics, Rosemary Roberts, MD Medical Officer, Pediatrics Team Center for Drug Evaluation and Research (Posted 7/08/1999)
- Update on the New FDA Office of Postmarketing Drug Risk Assessment (OPDRA): Beyond Spontaneous Reports Evelyn M. Rodriguez, MD, MPH Director, Division of Drug Risk Evaluation II (Posted 7/02/1999)
- Update on the New FDA Office of Postmarketing Drug Risk Assessment (OPDRA): Medication Error Program Jerry Phillips, RPh Associate Director, Medication Error Program (Posted 7/02/1999)
- Update on the New FDA Office of Postmarketing Drug Risk Assessment (OPDRA): Structure, Function and Initiatives Peter K Honig, MD, MPH (Posted 7/02/1999)
- What’s Changing in Postmarketing Surveillance?, Office Ralph Lillie, RPh, MPH Deputy Director, Office of Postmarketing Drug Risk Assessment (Posted 7/02/1999)
Last update: July 11, 2005 |
|
